Literature DB >> 11340661

Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.

B Mahalingam1, J M Louis, J Hung, R W Harrison, I T Weber.   

Abstract

Emergence of drug-resistant mutants of HIV-1 protease is an ongoing problem in the fight against AIDS. The mechanisms governing resistance are both complex and varied. We have determined crystal structures of HIV-1 protease mutants, D30N, K45I, N88D, and L90M complexed with peptide inhibitor analogues of CA-p2 and p2-NC cleavage sites in the Gag-pol precursor in order to study the structural mechanisms underlying resistance. The structures were determined at 1.55-1.9-A resolution and compared with the wild-type structure. The conformational disorder seen for most of the hydrophobic side-chains around the inhibitor binding site indicates flexibility of binding. Eight water molecules are conserved in all 9 structures; their location suggests that they are important for catalysis as well as structural stability. Structural differences among the mutants were analyzed in relation to the observed changes in protease activity and stability. Mutant L90M shows steric contacts with the catalytic Asp25 that could destabilize the catalytic loop at the dimer interface, leading to its observed decreased dimer stability and activity. Mutant K45I reduces the mobility of the flap and the inhibitor and contributes to an enhancement in structural stability and activity. The side-chain variations at residue 30 relative to wild-type are the largest in D30N and the changes are consistent with the altered activity observed with peptide substrates. Polar interactions in D30N are maintained, in agreement with the observed urea sensitivity. The side-chains of D30N and N88D are linked through a water molecule suggesting correlated changes at the two sites, as seen with clinical inhibitors. Structural changes seen in N88D are small; however, water molecules that mediate interactions between Asn88 and Thr74/Thr31/Asp30 in other complexes are missing in N88D. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340661     DOI: 10.1002/prot.1057

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  67 in total

1.  Computational analysis of HIV-1 protease protein binding pockets.

Authors:  Gene M Ko; A Srinivas Reddy; Sunil Kumar; Barbara A Bailey; Rajni Garg
Journal:  J Chem Inf Model       Date:  2010-10-25       Impact factor: 4.956

2.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

3.  Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.

Authors:  Mark D Shenderovich; Ron M Kagan; Peter N R Heseltine; Kal Ramnarayan
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

4.  Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease.

Authors:  Oscar Alvizo; Seema Mittal; Stephen L Mayo; Celia A Schiffer
Journal:  Protein Sci       Date:  2012-06-05       Impact factor: 6.725

5.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

6.  N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

Authors:  Yumi Mitsuya; Mark A Winters; W Jeffrey Fessel; Soo-Yon Rhee; Leo Hurley; Michael Horberg; Celia A Schiffer; Andrew R Zolopa; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2006-12       Impact factor: 2.205

7.  Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Authors:  Yuan-Fang Wang; Yunfeng Tie; Peter I Boross; Jozsef Tozser; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

8.  Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.

Authors:  Stefano Piana; Paolo Carloni; Ursula Rothlisberger
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

9.  Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation.

Authors:  Dan Li; Ying Zhang; Run-Ning Zhao; Song Fan; Ju-Guang Han
Journal:  J Mol Model       Date:  2014-02-14       Impact factor: 1.810

10.  Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Authors:  Arun K Ghosh; Jacqueline N Williams; Rachel Y Ho; Hannah M Simpson; Shin-Ichiro Hattori; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-10-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.